Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA® |
| June 26, 2018 | June 2018 Bond Updates |
|
BERGEN, Norway, June 26, 2018 BerGenBio ASA (OSE:BGBIO) announces today that on a top-line, preliminary basis, the first efficacy endpoint has been met in its Phase II clinical trial (BGBC008) evaluating bemcentinib, a first-in-class oral selective AXL inhibitor, in combination with the... |
| View more at: https://www.prnewswire.com/news-releases/selective-axl-inhibitor-bemcentinib-meets-pre-specified-efficacy-endpoint-in-stage-1-of-nsclc-phase-ii-combination-trial-with-keytruda-300672128.html |
| Related News |